Aclarion Inc (ACON)

$2.64 +0.04 (1.54%)
Market Cap 7.98M
Revenue (ttm) 80,000.00
Net Income (ttm) -7.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,037.50%
Debt to Equity Ratio 0.00
Volume 59,652
Avg Vol 60,118
Day's Range N/A - N/A
Shares Out 2.88M
Stochastic %K 62%
Beta 1.22
Analysts Sell
Price Target $7.50

Company Profile

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning inter...

Industry: Health Information Services
Sector: Healthcare
Phone: 833 275 2266
Address:
8181 Arista Place, Suite 100, Broomfield, United States
DragonOfBosnia
DragonOfBosnia Aug. 19 at 2:48 PM
$ACON added more
0 · Reply
Tradethestocks2323
Tradethestocks2323 Aug. 18 at 6:22 PM
$ACON 🟢 CFO buys +24k of $ACON at 2.45 increasing position +20%. 🔁 Following 4 other recent buys.
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 7:50 PM
$TDIC $GMM $MTR $ACON $OLOX peak
0 · Reply
Putnik
Putnik Aug. 17 at 7:42 PM
$ACON finally moving in right direction
0 · Reply
victorygin
victorygin Aug. 17 at 6:56 PM
$ACON lol wtf is this chart
0 · Reply
carefour
carefour Aug. 17 at 6:12 PM
$ACON in
0 · Reply
Atore
Atore Aug. 13 at 3:37 PM
$ACON $TGHL
0 · Reply
Putnik
Putnik Aug. 13 at 1:29 AM
$ACON all these low floaters china scams popping they should come here and pump this US stock
0 · Reply
Tradethestocks2323
Tradethestocks2323 Aug. 11 at 3:48 PM
$ACON
0 · Reply
Tradethestocks2323
Tradethestocks2323 Aug. 10 at 6:19 PM
$ACON
1 · Reply
Latest News on ACON
Aclarion receives notice of allowance for patent

2026-08-17T09:58:45.000Z - 2 days ago

Aclarion receives notice of allowance for patent

Aclarion Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Aclarion Quarterly report: Q2 2026

Aclarion Transcript: Planet MicroCap Las Vegas 2026

Jun 17, 2026, 11:30 AM EDT - 2 months ago

Aclarion Transcript: Planet MicroCap Las Vegas 2026

Aclarion partners with PRIA Healthcare to expand access to Nociscan

2026-06-09T13:24:57.000Z - 2 months ago

Aclarion partners with PRIA Healthcare to expand access to Nociscan

Aclarion rejects Echo Lake acquisition proposal

2026-06-08T11:28:03.000Z - 2 months ago

Aclarion rejects Echo Lake acquisition proposal

Aclarion to ‘carefully review and evaluate’ Echo Lake’s proposal

2026-05-28T18:55:11.000Z - 2 months ago

Aclarion to ‘carefully review and evaluate’ Echo Lake’s proposal

Echo Lake offers to acquire Aclarion for $4 per share in cash

2026-05-28T12:38:18.000Z - 2 months ago

Echo Lake offers to acquire Aclarion for $4 per share in cash

Echo Lake Capital Offers To Acquire Aclarion Inc.

May 28, 2026, 8:00 AM EDT - 2 months ago

Echo Lake Capital Offers To Acquire Aclarion Inc.

Aclarion Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Aclarion Quarterly report: Q1 2026

Aclarion enters second commercial agreement with Weill Cornell Medicine

2026-05-05T11:37:11.000Z - 3 months ago

Aclarion enters second commercial agreement with Weill Cornell Medicine

Aclarion Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Aclarion Proxy statement: Proxy filing

Aclarion announces $2.5M share repurchase program

2026-04-22T13:10:35.000Z - 4 months ago

Aclarion announces $2.5M share repurchase program

Aclarion granted U.S. patent for AI-driven back pain assessment

2026-04-16T10:52:45.000Z - 4 months ago

Aclarion granted U.S. patent for AI-driven back pain assessment

Aclarion Receives Pinnacle Award for AI Innovation

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Aclarion Receives Pinnacle Award for AI Innovation

Aclarion announces commercial agreement with Weill Cornell Medicine

2026-04-08T12:21:37.000Z - 4 months ago

Aclarion announces commercial agreement with Weill Cornell Medicine

Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video

Apr 7, 2026, 8:00 AM EDT - 4 months ago

Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video

Aclarion Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 4 months ago

Aclarion Proxy statement: Proxy filing

Echo Lake calls on Aclarion director David Neal to resign

2026-03-24T12:25:45.000Z - 5 months ago

Echo Lake calls on Aclarion director David Neal to resign

Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc.

Mar 24, 2026, 8:00 AM EDT - 5 months ago

Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc.

Aclarion adopts limited duration stockholder rights plan

2026-03-19T13:37:04.000Z - 5 months ago

Aclarion adopts limited duration stockholder rights plan

Aclarion’s CEO publishes shareholder letter

2026-03-19T10:11:08.000Z - 5 months ago

Aclarion’s CEO publishes shareholder letter

Aclarion Annual report: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 5 months ago

Aclarion Annual report: Q4 2025

Aclarion strengthens balance sheet, extends cash runway into 2028

2026-01-13T11:11:19.000Z - 7 months ago

Aclarion strengthens balance sheet, extends cash runway into 2028

Aclarion Inc trading resumes

2026-01-08T15:05:25.000Z - 7 months ago

Aclarion Inc trading resumes

Aclarion Inc trading halted, volatility trading pause

2026-01-08T15:00:34.000Z - 7 months ago

Aclarion Inc trading halted, volatility trading pause

Why Is Aclarion Stock (ACON) Up Today?

2026-01-08T13:03:55.000Z - 7 months ago

Why Is Aclarion Stock (ACON) Up Today?

Aclarion says first patients enrolled at two additional CLARITY trial sites

2026-01-06T11:20:12.000Z - 8 months ago

Aclarion says first patients enrolled at two additional CLARITY trial sites

Aclarion announces publication of Nociscan article in pain issue of IJSS

2025-12-04T13:15:42.000Z - 9 months ago

Aclarion announces publication of Nociscan article in pain issue of IJSS

Aclarion appoints Jason Brosniak as commercial director, Eastern U.S.

2025-12-02T13:10:19.000Z - 9 months ago

Aclarion appoints Jason Brosniak as commercial director, Eastern U.S.

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Dec 2, 2025, 8:00 AM EST - 9 months ago

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Aclarion Quarterly report: Q3 2025

Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Oct 22, 2025, 6:00 AM EDT - 10 months ago

Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Aclarion Transcript: LD Micro Main Event XIX Investor Conference

Oct 20, 2025, 3:00 PM EDT - 10 months ago

Aclarion Transcript: LD Micro Main Event XIX Investor Conference

Aclarion to Present at the LD Micro Main Event XIX

Oct 9, 2025, 6:00 AM EDT - 11 months ago

Aclarion to Present at the LD Micro Main Event XIX

Aclarion Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Aclarion Quarterly report: Q2 2025

Aclarion Proxy statement: Proxy Filing

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Aclarion Proxy statement: Proxy Filing

Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

Jun 24, 2025, 7:00 AM EDT - 1 year ago

Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

May 20, 2025, 6:00 AM EDT - 1 year ago

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

Aclarion Quarterly report: Q1 2025

May 14, 2025, 6:00 PM EDT - 1 year ago

Aclarion Quarterly report: Q1 2025

Aclarion Proxy statement: Proxy Filing

May 13, 2025, 8:00 AM EDT - 1 year ago

Aclarion Proxy statement: Proxy Filing

Aclarion Announces Texas Back Institute as New CLARITY Trial Site

May 12, 2025, 7:34 AM EDT - 1 year ago

Aclarion Announces Texas Back Institute as New CLARITY Trial Site

Aclarion Proxy statement: Proxy Filing

May 2, 2025, 8:00 AM EDT - 1 year ago

Aclarion Proxy statement: Proxy Filing

Aclarion Slides: Corporate Presentation

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Aclarion Slides: Corporate Presentation

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Apr 29, 2025, 6:00 AM EDT - 1 year ago

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Aclarion Registration statement: Registration Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Aclarion Registration statement: Registration Filing

Aclarion Transcript: Planet MicroCap Showcase VEGAS 2025

Apr 23, 2025, 12:00 PM EDT - 1 year ago

Aclarion Transcript: Planet MicroCap Showcase VEGAS 2025

Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Apr 23, 2025, 6:00 AM EDT - 1 year ago

Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Apr 21, 2025, 6:00 AM EDT - 1 year ago

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

Apr 9, 2025, 7:00 AM EDT - 1 year ago

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

Aclarion Annual report: Q4 2024

Apr 8, 2025, 6:00 PM EDT - 1 year ago

Aclarion Annual report: Q4 2024

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

Apr 2, 2025, 6:00 AM EDT - 1 year ago

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

Aclarion Provides Shareholder Update

Mar 13, 2025, 9:25 AM EDT - 1 year ago

Aclarion Provides Shareholder Update

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Mar 6, 2025, 9:35 AM EST - 1 year ago

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Aclarion Announces First Commercial Agreement with Scripps Health

Mar 3, 2025, 6:00 AM EST - 1 year ago

Aclarion Announces First Commercial Agreement with Scripps Health

Aclarion Proxy statement: Proxy Filing

Feb 28, 2025, 7:00 AM EST - 1 year ago

Aclarion Proxy statement: Proxy Filing

Aclarion Slides: Corporate Presentation

Feb 20, 2025, 6:00 PM EST - 1 year ago

Aclarion Slides: Corporate Presentation

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit

Feb 20, 2025, 6:00 AM EST - 1 year ago

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Feb 11, 2025, 7:58 AM EST - 1 year ago

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Feb 6, 2025, 7:23 AM EST - 1 year ago

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

Feb 4, 2025, 7:23 AM EST - 1 year ago

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

Aclarion Proxy statement: Proxy Filing

Feb 3, 2025, 7:00 AM EST - 1 year ago

Aclarion Proxy statement: Proxy Filing

Aclarion Proxy statement: Proxy Filing

Jan 22, 2025, 7:00 AM EST - 1 year ago

Aclarion Proxy statement: Proxy Filing

Aclarion Registration statement: Registration Filing

Jan 10, 2025, 7:00 AM EST - 1 year ago

Aclarion Registration statement: Registration Filing

Aclarion Registration statement: Registration Filing

Dec 26, 2024, 7:00 AM EST - 1 year ago

Aclarion Registration statement: Registration Filing

Aclarion Registration statement: Registration Filing

Dec 11, 2024, 7:00 AM EST - 1 year ago

Aclarion Registration statement: Registration Filing

Aclarion Proxy statement: Proxy Filing

Dec 2, 2024, 7:00 AM EST - 1 year ago

Aclarion Proxy statement: Proxy Filing

Aclarion Transcript: Investor Update

Nov 23, 2024, 7:00 AM EST - 1 year ago

Aclarion Transcript: Investor Update

Aclarion Proxy statement: Proxy Filing

Nov 22, 2024, 7:00 AM EST - 1 year ago

Aclarion Proxy statement: Proxy Filing

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Nov 21, 2024, 8:00 AM EST - 1 year ago

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

Nov 14, 2024, 5:00 PM EST - 1 year ago

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

Aclarion Quarterly report: Q3 2024

Nov 13, 2024, 6:00 PM EST - 1 year ago

Aclarion Quarterly report: Q3 2024

Aclarion Registration statement: Registration Filing

Nov 4, 2024, 7:00 AM EST - 1 year ago

Aclarion Registration statement: Registration Filing

Aclarion Registration statement: Registration Filing

Oct 25, 2024, 8:00 AM EDT - 1 year ago

Aclarion Registration statement: Registration Filing

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 7:00 AM EDT - 2 years ago

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Sep 27, 2024, 6:57 AM EDT - 2 years ago

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Aclarion Registration statement: Registration Filing

Sep 19, 2024, 8:00 AM EDT - 2 years ago

Aclarion Registration statement: Registration Filing

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Sep 13, 2024, 8:30 AM EDT - 2 years ago

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Sep 12, 2024, 6:57 AM EDT - 2 years ago

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Sep 10, 2024, 6:57 AM EDT - 2 years ago

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Aclarion Registration statement: Registration Filing

Sep 9, 2024, 8:00 AM EDT - 2 years ago

Aclarion Registration statement: Registration Filing

Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market

Sep 5, 2024, 6:57 AM EDT - 2 years ago

Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market

Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

Aug 29, 2024, 6:57 AM EDT - 2 years ago

Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

Aclarion Proxy statement: Proxy Filing

Aug 26, 2024, 8:00 AM EDT - 2 years ago

Aclarion Proxy statement: Proxy Filing

Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans

Aug 21, 2024, 7:57 AM EDT - 2 years ago

Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans

Aclarion Transcript: Investor Update

Aug 20, 2024, 4:00 AM EDT - 2 years ago

Aclarion Transcript: Investor Update

Aclarion Proxy statement: Proxy Filing

Aug 16, 2024, 8:00 AM EDT - 2 years ago

Aclarion Proxy statement: Proxy Filing

Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

Aug 15, 2024, 9:48 AM EDT - 2 years ago

Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

Aclarion Announces First Commercial Agreement in Michigan

Aug 14, 2024, 8:08 AM EDT - 2 years ago

Aclarion Announces First Commercial Agreement in Michigan

Aclarion Quarterly report: Q2 2024

Aug 13, 2024, 6:00 PM EDT - 2 years ago

Aclarion Quarterly report: Q2 2024

Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

Aug 13, 2024, 9:07 AM EDT - 2 years ago

Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Jul 9, 2024, 7:00 AM EDT - 2 years ago

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

Jun 26, 2024, 8:30 AM EDT - 2 years ago

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

Jun 25, 2024, 8:30 AM EDT - 2 years ago

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

Aclarion Quarterly report: Q1 2024

May 14, 2024, 6:00 PM EDT - 2 years ago

Aclarion Quarterly report: Q1 2024

Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

Apr 25, 2024, 9:14 AM EDT - 2 years ago

Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

Aclarion Annual report: Q4 2023

Mar 27, 2024, 7:00 PM EDT - 2 years ago

Aclarion Annual report: Q4 2023

Aclarion Announces Closing of $3.0 Million Public Offering

Feb 27, 2024, 3:22 PM EST - 2 years ago

Aclarion Announces Closing of $3.0 Million Public Offering

Aclarion Announces Pricing of $3.0 Million Public Offering

Feb 26, 2024, 9:15 AM EST - 2 years ago

Aclarion Announces Pricing of $3.0 Million Public Offering

Aclarion Registration statement: Registration Filing

Feb 23, 2024, 7:00 AM EST - 2 years ago

Aclarion Registration statement: Registration Filing

Aclarion Registration statement: Registration Filing

Feb 21, 2024, 7:00 AM EST - 2 years ago

Aclarion Registration statement: Registration Filing

Aclarion Registration statement: Registration Filing

Feb 6, 2024, 7:00 AM EST - 2 years ago

Aclarion Registration statement: Registration Filing

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Feb 5, 2024, 8:00 AM EST - 2 years ago

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Aclarion Registration statement: Registration Filing

Jan 31, 2024, 7:00 AM EST - 2 years ago

Aclarion Registration statement: Registration Filing

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Jan 22, 2024, 8:00 AM EST - 2 years ago

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Aclarion Registration statement: Registration Filing

Jan 22, 2024, 7:00 AM EST - 2 years ago

Aclarion Registration statement: Registration Filing

Aclarion Registration statement: Registration Filing

Dec 11, 2023, 7:00 AM EST - 2 years ago

Aclarion Registration statement: Registration Filing

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Nov 27, 2023, 8:00 AM EST - 2 years ago

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Aclarion Quarterly report: Q3 2023

Nov 13, 2023, 6:00 PM EST - 3 years ago

Aclarion Quarterly report: Q3 2023

Aclarion Proxy statement: Proxy Filing

Nov 13, 2023, 7:00 AM EST - 3 years ago

Aclarion Proxy statement: Proxy Filing

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Nov 6, 2023, 8:00 AM EST - 3 years ago

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Aclarion Proxy statement: Proxy Filing

Nov 1, 2023, 8:00 AM EDT - 3 years ago

Aclarion Proxy statement: Proxy Filing

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

Oct 25, 2023, 8:30 AM EDT - 3 years ago

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Oct 24, 2023, 8:45 AM EDT - 3 years ago

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan

Oct 23, 2023, 7:00 AM EDT - 3 years ago

Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan

Aclarion Registration statement: Registration Filing

Oct 20, 2023, 8:00 AM EDT - 3 years ago

Aclarion Registration statement: Registration Filing

Aclarion Registration statement: Registration Filing

Oct 10, 2023, 8:00 AM EDT - 3 years ago

Aclarion Registration statement: Registration Filing

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

Aug 25, 2023, 4:10 PM EDT - 3 years ago

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

DragonOfBosnia
DragonOfBosnia Aug. 19 at 2:48 PM
$ACON added more
0 · Reply
Tradethestocks2323
Tradethestocks2323 Aug. 18 at 6:22 PM
$ACON 🟢 CFO buys +24k of $ACON at 2.45 increasing position +20%. 🔁 Following 4 other recent buys.
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 7:50 PM
$TDIC $GMM $MTR $ACON $OLOX peak
0 · Reply
Putnik
Putnik Aug. 17 at 7:42 PM
$ACON finally moving in right direction
0 · Reply
victorygin
victorygin Aug. 17 at 6:56 PM
$ACON lol wtf is this chart
0 · Reply
carefour
carefour Aug. 17 at 6:12 PM
$ACON in
0 · Reply
Atore
Atore Aug. 13 at 3:37 PM
$ACON $TGHL
0 · Reply
Putnik
Putnik Aug. 13 at 1:29 AM
$ACON all these low floaters china scams popping they should come here and pump this US stock
0 · Reply
Tradethestocks2323
Tradethestocks2323 Aug. 11 at 3:48 PM
$ACON
0 · Reply
Tradethestocks2323
Tradethestocks2323 Aug. 10 at 6:19 PM
$ACON
1 · Reply
Putnik
Putnik Aug. 6 at 7:56 PM
$ACON it would be great if this shit went to $4 range before clarity trial news cuz then I am sure $8 to $12 would come
0 · Reply
BioTuesdays
BioTuesdays Aug. 4 at 6:19 PM
$ACON has announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking the first site in Indiana to offer the technology. https://biotuesdays.com/2026/08/04/first-site-in-indiana-offers-aclarions-nociscan-for-lower-back-pain/
0 · Reply
SA449
SA449 Aug. 3 at 2:05 PM
$ACON
0 · Reply
Putnik
Putnik Aug. 3 at 1:08 PM
$ACON can we start a true reversal from here to clarity trial news! Come on!
0 · Reply
Putnik
Putnik Aug. 3 at 2:15 AM
$ACON can we hold any gains for fuck sake!
0 · Reply
Putnik
Putnik Jul. 31 at 6:58 PM
$ACON we are green on a Friday hmm interesting. Could it be that these fucks started buying back? I mean they could buy half the float at this price lol
1 · Reply
MJag6969
MJag6969 Jul. 31 at 6:00 PM
$ACON You guys are showing signs of life here....
0 · Reply
MJag6969
MJag6969 Jul. 30 at 11:03 PM
$ACON Somebody pitch me here..why should I dump 20k in here for 10 thousand shares. - There is the low float which mostly consist of warrants and shares at 5.18 - There is the offer that they turned down for 4 per share. Which makes sense because they would sell the company at 10m while having 16m in cash - there is the 2.5m dollar worth of share buy back. Thinking like scam management here now --- I would buy in but not at this price. If I was them I would ride this 15 days into delisting.... Bring it down to it's knees and than buy up 3/4 of the float. ... Any other thoughts ? Ideas other than it's scam, bs, they belong in jail. Yes we know that. They all belong in jail.
1 · Reply
Huskersnsaints
Huskersnsaints Jul. 30 at 6:04 PM
$ACON with the cash position this stock should be trading at the $5.00 and above level but no one seems to trust the managment!!!!
1 · Reply
Apes_Strong
Apes_Strong Jul. 30 at 3:14 PM
$ACON jail this management and out the cash in the hands of credible honest management Tharmann is a criminal
0 · Reply